Aliases & Classifications for Substance Abuse

MalaCards integrated aliases for Substance Abuse:

Name: Substance Abuse 12 29 15
Substance-Related Disorders 43 71
Substance Abuse Problem 71

Classifications:



External Ids:

Disease Ontology 12 DOID:302
MeSH 43 D019966
NCIt 49 C16522
SNOMED-CT 67 26416006
UMLS 71 C0013146 C0236969 C0740858

Summaries for Substance Abuse

Disease Ontology : 12 A substance-related disorder that involves a maladaptive pattern of substance use leading to significant impairment in functioning.

MalaCards based summary : Substance Abuse, also known as substance-related disorders, is related to depression and cannabis abuse, and has symptoms including symptoms An important gene associated with Substance Abuse is MIAT (Myocardial Infarction Associated Transcript), and among its related pathways/superpathways are Peptide ligand-binding receptors and Transmission across Chemical Synapses. The drugs Acetylcholine and Ritonavir have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and liver, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Wikipedia : 74 Substance abuse, also known as drug abuse, is use of a drug in amounts or by methods which are harmful... more...

Related Diseases for Substance Abuse

Diseases in the Substance Abuse family:

T-Substance Anomaly

Diseases related to Substance Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 365)
# Related Disease Score Top Affiliating Genes
1 depression 33.6 SLC6A4 MAOA BDNF
2 cannabis abuse 33.4 GABRA2 DRD4 DRD2 COMT BDNF
3 opioid abuse 33.4 DRD5 DRD3 DRD2 CYP2D6
4 amphetamine abuse 33.3 SLC6A4 SLC6A3 HTR1B DRD5 DRD4
5 alcohol use disorder 33.3 SLC6A4 SLC6A3 HTR1B GABRA2 DRD3 DRD2
6 eating disorder 33.3 SLC6A4 SLC6A3 NPY DRD3 DRD2 COMT
7 schizoaffective disorder 33.2 SLC6A4 PRL DRD4 DRD3 DRD2 COMT
8 borderline personality disorder 33.2 SLC6A4 SLC6A3 PRL MAOA HTR1B DRD2
9 cocaine abuse 33.1 SLC6A4 SLC6A3 PRL MOBP DRD3 DRD2
10 bipolar disorder 32.9 SLC6A4 SLC6A3 PRL MAOA HTR1B GABRA2
11 schizophrenia 32.3 SLC6A4 SLC6A3 PRL NPY MOBP MIAT
12 personality disorder 31.9 SLC6A4 SLC6A3 PRL MAOA HTR1B DRD4
13 drug dependence 31.9 SLC6A4 SLC6A3 NPY GABRA2 DRD3 DRD2
14 avoidant personality disorder 31.9 SLC6A4 SLC6A3 MAOA HTR1B DRD4 DRD3
15 brain injury 31.8 DRD2 COMT BDNF
16 disease of mental health 31.8 SLC6A4 SLC6A3 NPY MAOA DRD5 DRD4
17 traumatic brain injury 31.8 DRD2 COMT BDNF
18 opiate dependence 31.8 SLC6A4 SLC6A3 DRD4 DRD3 DRD2
19 alcohol dependence 31.8 SLC6A4 SLC6A3 PRL NPY MAOA HTR1B
20 conduct disorder 31.7 SLC6A4 SLC6A3 MAOA GABRA2 DRD5 DRD4
21 substance dependence 31.6 SLC6A4 SLC6A3 MAOA HTR1B GABRA2 DRD5
22 polysubstance abuse 31.6 DRD3 DRD2 COMT
23 antisocial personality disorder 31.6 SLC6A4 SLC6A3 PRL MAOA HTR1B GABRA2
24 post-traumatic stress disorder 31.6 SLC6A4 NPY MAOA DRD2 DBH COMT
25 mental depression 31.5 SLC6A4 SLC6A3 MAOA HTR1B DRD4 DRD2
26 mood disorder 31.5 SLC6A4 SLC6A3 NPY MAOA HTR1B DRD4
27 alexithymia 31.4 SLC6A4 DRD2 COMT
28 tobacco addiction 31.4 SLC6A4 SLC6A3 MAOA GABRA2 DRD5 DRD4
29 cocaine dependence 31.4 SLC6A4 SLC6A3 PRL HTR1B GABRA2 DRD3
30 anxiety 31.4 SLC6A4 SLC6A3 PRL NPY MAOA HTR1B
31 adjustment disorder 31.3 SLC6A4 NPY BDNF
32 pathological gambling 31.3 SLC6A4 SLC6A3 MAOA DRD5 DRD4 DRD3
33 dysthymic disorder 31.3 SLC6A4 MAOA BDNF
34 social phobia 31.3 SLC6A4 PRL MAOA DRD2 COMT
35 agoraphobia 31.2 SLC6A4 MAOA COMT
36 psychotic disorder 31.2 SLC6A4 SLC6A3 PRL MAOA DRD5 DRD4
37 anorexia nervosa 31.2 SLC6A4 PRL NPY MAOA DRD4 COMT
38 sleep disorder 31.2 SLC6A4 SLC6A3 PRL DRD2 BDNF
39 attention deficit-hyperactivity disorder 31.2 SLC6A4 SLC6A3 PRL NPY MAOA HTR1B
40 generalized anxiety disorder 31.2 SLC6A4 SLC6A3 NPY MAOA DRD2 CYP2D6
41 bipolar i disorder 31.1 SLC6A4 DRD4 DRD3 DRD2 COMT BDNF
42 postpartum depression 31.1 SLC6A4 PRL MAOA COMT BDNF
43 opioid addiction 31.1 DRD2 COMT
44 oppositional defiant disorder 31.1 SLC6A4 SLC6A3 MAOA DRD4 DRD2 DBH
45 sexual disorder 31.1 SLC6A4 PRL DRD2 CYP2D6
46 amnestic disorder 31.0 DRD2 BDNF BCHE
47 major depressive disorder 31.0 SLC6A4 SLC6A3 PRL NPY MAOA HTR1B
48 tardive dyskinesia 31.0 DRD3 DRD2 CYP2D6 COMT
49 bulimia nervosa 31.0 SLC6A4 PRL NPY MAOA HTR1B DRD4
50 neurotic disorder 31.0 SLC6A4 MAOA BDNF

Graphical network of the top 20 diseases related to Substance Abuse:



Diseases related to Substance Abuse

Symptoms & Phenotypes for Substance Abuse

UMLS symptoms related to Substance Abuse:


symptoms

MGI Mouse Phenotypes related to Substance Abuse:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.16 BDNF COMT CYBB DBH DRD2 DRD3
2 endocrine/exocrine gland MP:0005379 9.81 BDNF COMT DBH DRD2 DRD5 HTR1B
3 homeostasis/metabolism MP:0005376 9.8 BCHE BDNF COMT CYBB DBH DRD2
4 nervous system MP:0003631 9.5 BDNF COMT CYBB DBH DRD2 DRD3

Drugs & Therapeutics for Substance Abuse

Drugs for Substance Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 494)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
3
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
4
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
5
Nicotine Approved Phase 4 54-11-5 942 89594
6
Lithium carbonate Approved Phase 4 554-13-2
7
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
8
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
9
Desipramine Approved, Investigational Phase 4 50-47-5 2995
10
Memantine Approved, Investigational Phase 4 19982-08-2 4054
11
Clonidine Approved Phase 4 4205-90-7 2803
12
Baclofen Approved Phase 4 1134-47-0 2284
13
Amantadine Approved Phase 4 768-94-5 2130
14
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
15
Histamine Approved, Investigational Phase 4 51-45-6 774
16
Acetaminophen Approved Phase 4 103-90-2 1983
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
19
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
20
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
21
Ziprasidone Approved Phase 4 146939-27-7 60854
22
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
23
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
24
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
25
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
26
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
27
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
28
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
29
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
30
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
31
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
32
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
33
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
34
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
35
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
36
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
37
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
38
Cobicistat Approved Phase 4 1004316-88-4
39
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
40
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
41
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
42
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
43
Desogestrel Approved Phase 4 54024-22-5 40973
44
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
45
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
46
Cocaine Approved, Illicit Phase 4 50-36-2 5760 446220
47
Methadone Approved Phase 4 76-99-3 4095
48
Clozapine Approved Phase 4 5786-21-0 2818
49
Morphine Approved, Investigational Phase 4 57-27-2 5288826
50
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603

Interventional clinical trials:

(show top 50) (show all 2010)
# Name Status NCT ID Phase Drugs
1 Cognitive Correlates of Substance Abuse, Part 1 Unknown status NCT00000346 Phase 4
2 Smoking Cessation Treatment for Methadone Maintenance Patients Unknown status NCT01027754 Phase 4 Varenicline;Placebo
3 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
4 Association Between Motorcycle Accidents, Attention Deficit/Hyperactivity Disorder and Substance Use Disorder and Motorcycle Accidents Unknown status NCT00536419 Phase 4 Methylphenidate
5 Study of Associated Gene Polymorphisms With Atomoxetine Response Prediction in ADHD Treatment Unknown status NCT01339286 Phase 4 atomoxetine
6 Aggressive Behaviour in Children With Tourette's Syndrome (TS) and Comorbid Attention Deficit Hyperactivity Disorder (ADHD) Unknown status NCT00152750 Phase 4 APO-clonidine
7 Three Strategies for Implementing Motivational Interviewing on Medical Inpatient Units: See One, Do One, Order One Unknown status NCT01825057 Phase 4
8 A Multi-Center,Open-Labeled,Intervention Study:The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation Unknown status NCT02935998 Phase 4 Ziprasidone
9 A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD) Unknown status NCT01556971 Phase 4 Botox;Saline Solution
10 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
11 Depakote ER Therapy for Mania Comorbid With Substance Abuse Completed NCT00208195 Phase 4 Divalproex ER
12 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
13 The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients Completed NCT00295412 Phase 4 quetiapine (drug)
14 Pilot Study of Vyvanse™ (Lisdexamfetamine Dimesylate) in Adolescents (Ages 11-15) With ADHD and an Older Sibling With ADHD and Substance Dependence Completed NCT00573534 Phase 4 Vyvanse
15 Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
16 Relapse Prevention With Varenicline Completed NCT00944554 Phase 4 Varenicline;Placebo
17 Translating Depression Guidelines Into Substance Abuse Treatment Completed NCT00137306 Phase 4
18 A Double-blind Placebo Controlled Trial of Pregnenolone for Depression in Patients With Bipolar Disorders or Recurrent Major Depressive Disorder and a History of Substance Abuse Completed NCT00223197 Phase 4 Pregnenolone
19 Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized Trial (BRAVO) Completed NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
20 On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings Completed NCT00317460 Phase 4
21 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
22 Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone Completed NCT00208143 Phase 4 Quetiapine;Risperidone
23 Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder Completed NCT00203528 Phase 4 divalproex sodium ER;risperidone
24 Atomoxetine in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorder (SUD) Completed NCT00218322 Phase 4 Atomoxetine hydrochloride;Placebo
25 Improving Hepatitis C Treatment in Injection Drug Users Completed NCT00148031 Phase 4 Pegylated Interferon and Ribavirin
26 Methamphetamine Abuse Pharmacology in Patients With AIDS Completed NCT00000321 Phase 4 Desipramine
27 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4 Paroxetine CR
28 Prevention Services in Schools for Early Drug Abuse Risk Completed NCT00257088 Phase 4
29 Efficacy of Quetiapine in the Reduction of Cocaine Use and Cravings in Individuals With Cocaine Dependence Completed NCT00232336 Phase 4 quetiapine
30 Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia Completed NCT00156715 Phase 4 Quetiapine
31 Efficacy & Safety of Baclofen to Reduce Alcohol Use in Veterans With HCV Completed NCT01008280 Phase 4 baclofen;placebo
32 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4 Bupropion
33 Brain Changes in Stimulant Dependent Subjects Completed NCT00000343 Phase 4
34 Pharmacotherapy and Intensive Treatment Completed NCT00000218 Phase 4 Carbamazepine
35 Methylphenidate Raclopride PET Test Completed NCT00015301 Phase 4 Methylphenidate
36 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence Completed NCT00015275 Phase 4
37 Modeling Impaired Judgement in Cocaine Abusers Completed NCT00015236 Phase 4
38 A Prospective Cohort Study Comparing the Effectiveness of Zepatier for the Treatment of Hepatitis C in an Academic Center Population to People Who Inject Drugs (PWIDs) in a Safety Net Clinic Setting Engaged in Either a Medication Assisted Therapy (MAT) or Syringe Exchange Program Completed NCT03093415 Phase 4 elbasvir-grazoprevir (50 mg/100 mg)
39 Effectiveness of Naltrexone in a Community Setting Completed NCT00000445 Phase 4 naltrexone (Revia)
40 Abuse Liability of Controlled-Release Oxycodone Formulations Completed NCT02101840 Phase 4 Apo-Oxycodone CR®;OxyNEO®;Placebo
41 Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study Completed NCT00015340 Phase 4 Buprenorphine/naloxone
42 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
43 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
44 The Effects of Intranasal Oxytocin on Social Cognition, Implicit Preferences and Craving in Moderate to Heavy Social Alcohol Drinkers Completed NCT01829516 Phase 4 Oxytocin;Placebo
45 Drug Contextual Conditioning With in Humans: Causes and Consequences Completed NCT03075501 Phase 4 Stimulant or sedative;Placebo
46 Substance Dependent Teens - Impact of Treating Depression Study 1 Completed NCT00061113 Phase 4 Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
47 Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug Abusers Completed NCT00685620 Phase 4
48 Treatment of Acute Hepatitis C Virus Infection in Injection Drug Users With Pegylated Interferon for 24 Weeks Completed NCT00194480 Phase 4 Pegylated Interferon
49 Vilazodone for Separation Anxiety Disorder Completed NCT01999920 Phase 4 Vilazodone;Placebo
50 Field Study of Smoking Cessation in Alcoholism Treatment Completed NCT00000454 Phase 4 nicotine replacement patch

Search NIH Clinical Center for Substance Abuse

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Desipramine
Desipramine Hydrochloride
Doxapram
Doxapram Hydrochloride

Cochrane evidence based reviews: substance-related disorders

Genetic Tests for Substance Abuse

Genetic tests related to Substance Abuse:

# Genetic test Affiliating Genes
1 Substance Abuse 29

Anatomical Context for Substance Abuse

MalaCards organs/tissues related to Substance Abuse:

40
Brain, Testes, Liver, Cortex, Heart, Spinal Cord, Kidney

Publications for Substance Abuse

Articles related to Substance Abuse:

(show top 50) (show all 23704)
# Title Authors PMID Year
1
Substance use disorder treatment services for pregnant and postpartum women in residential and outpatient settings. 61
31952630 2020
2
Peer support specialists and perinatal opioid use disorder: Someone that's been there, lived it, seen it. 61
31794901 2020
3
Gender Differences in Complex Posttraumatic Stress Symptoms, and Their Relationship to Mental Health and Substance Abuse Outcomes in Incarcerated Adults. 61
29294660 2020
4
The availability of retail tobacco near federally qualified healthcare facilities and addiction treatment centers in New York State. 61
31956471 2020
5
Basolateral amygdala - nucleus accumbens circuitry regulates optimal cue-guided risk/reward decision making. 61
31811876 2020
6
Normative Influences on the Role of Prescription Medicine Misuse among College Students in the United States. 61
30628463 2020
7
Editorial: Advances in understanding self-determination, mindfulness approaches, and behavioral interventions, outcomes in autistic siblings and substance abuse in neurodevelopmental disorders. 61
31833948 2020
8
Predicting Attrition and Engagement in the Treatment of Young Offenders. 61
31559878 2020
9
Psychosocial Correlates and Early Substance Abuse Associated With Lifetime Hallucinogen Use Among Hispanic Young Adults. 61
31424280 2020
10
Substance abuse-related admissions in a mixed Norwegian intensive care population. 61
31721148 2020
11
The Assessment of Recovery Capital (ARC) predicts substance abuse treatment completion. 61
31778848 2020
12
Mechanical stimulation of cervical vertebrae modulates the discharge activity of ventral tegmental area neurons and dopamine release in the nucleus accumbens. 61
31866493 2020
13
Managing Delirium and Agitation in the Older Emergency Department Patient: The ADEPT Tool. 61
31563402 2020
14
Worldwide research output trends on drinking and driving from 1956 to 2015. 61
31783335 2020
15
The MINDBODYSTRONG Intervention for New Nurse Residents: 6-Month Effects on Mental Health Outcomes, Healthy Lifestyle Behaviors, and Job Satisfaction. 61
31721425 2020
16
Association between MMPI-2-RF SUB items/scale and interview-reported substance abuse history among forensic psychiatric inpatients. 61
31512901 2020
17
Comparison of Opioid Prescription Patterns and Consumption Following Otologic Surgery. 61
31688613 2020
18
The Impact of Substance Abuse on Heart Failure Hospitalizations. 61
31369724 2020
19
Socioeconomic gradients of adverse birth outcomes and related maternal factors in rural and urban Alberta, Canada: a concentration index approach. 61
32014876 2020
20
Mental Health Care Access Using Geographic Information Systems: An Integrative Review. 61
31661647 2020
21
Chronic Care for Attention-Deficit/Hyperactivity Disorder: Clinical Management from Childhood Through Adolescence. 61
31996572 2020
22
Variables associated with low, moderate and high emergency department use among patients with substance-related disorders. 61
31887605 2020
23
Event-Related Electrodermal Response to Stress: Results From a Realistic Driving Simulator Scenario. 61
31050918 2020
24
Risk Factors and Services to Reduce Child Sexual Abuse Recurrence. 61
31084196 2020
25
Opioid Misuse Risk: Implementing Screening Protocols in an Ambulatory Oncology Clinic. 61
31961849 2020
26
Disclosure, concealment, and dishonesty in psychotherapy: A clinically focused review. 61
31746459 2020
27
Three-year longitudinal cognitive functioning in patients recently diagnosed with bipolar disorder. 61
31840225 2020
28
Post-traumatic stress burden in a sample of hospitalized patients with Bipolar Disorder: Which impact on clinical correlates and suicidal risk? 61
31732278 2020
29
Placental Histopathology in Late Preterm infants: Clinical Implications. 61
32024344 2020
30
A role for the neuropeptide somatostatin in the neurobiology of behaviors associated with substances abuse and affective disorders. 61
32027909 2020
31
Prevalence of Substance Abuse (Tobacco, Alcohol, Narcotics and Psychotropic Drugs) and Its Relationship to Family Factors in Pre-university Male Students in Shiraz 2017-2018. 61
31471833 2020
32
Help seeking behaviors of Latinos with substance use disorders who perceive a need for treatment: Substance abuse versus mental health treatment services. 61
31856949 2020
33
Are sweetened drinks a gateway to alcohol, opiate and stimulant addiction? Summary of evidence and therapeutic strategies. 61
31733533 2020
34
Prevalence of depression, anxiety, and substance-related disorders in parents of children with cerebral palsy: a systematic review. 61
31381150 2020
35
Changes in Medicaid Acceptance by Substance Abuse Treatment Facilities After Implementation of Federal Parity. 61
31688556 2020
36
Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States. 61
32031650 2020
37
Telehealth Increases Access to Care for Children Dealing with Suicidality, Depression, and Anxiety in Rural Emergency Departments. 61
32013779 2020
38
Modeling of self-report behavior data using the generalized covariates in a uniform and shifted binomial mixture model: An empirical example and Monte Carlo simulation. 61
31107041 2020
39
A Systematic Review of Indian Boarding Schools and Attachment in the Context of Substance Use Studies of Native Americans. 61
31452147 2020
40
Within-animal comparisons of novelty and cocaine neuronal ensemble overlap in the nucleus accumbens and prefrontal cortex. 61
31614186 2020
41
Differing trajectories of adversity over the life course: Implications for adult health and well-being. 61
32032803 2020
42
Innovations in pre-doctoral dental education: Influencing attitudes and opinions about patients with substance use disorder. 61
32022269 2020
43
The Role of Substance Use and Resiliency Factors on Suicidal Ideation among Middle School Students. 61
31828795 2020
44
What lessons have we learnt about the impact of maternal cigarette smoking from animal models? 61
31556137 2020
45
Substance Use Disorders in Later Life: A Review and Synthesis of the Literature of an Emerging Public Health Concern. 61
31340887 2020
46
Conceptualizing and measuring sustainability of prevention programs, policies, and practices. 61
31764968 2020
47
Trends and clinical features of intentional and accidental adult foreign body ingestions in the United States, 2000 to 2017. 61
31526812 2020
48
Use and Misuse of Opioids After Endocrine Surgery Operations. 61
31972644 2020
49
Opioid Prescriptions After Hemorrhoidectomy. 61
32015286 2020
50
Sex Differences, Cocaine Use, and Liver Fibrosis Among African Americans in the Miami Adult Studies on HIV Cohort. 61
32004098 2020

Variations for Substance Abuse

Expression for Substance Abuse

Search GEO for disease gene expression data for Substance Abuse.

Pathways for Substance Abuse

Pathways related to Substance Abuse according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.49 PRL NPY HTR1B GABRA2 DRD5 DRD4
2
Show member pathways
12.88 SLC6A4 SLC6A3 MAOA GABRA2 COMT BCHE
3
Show member pathways
12.69 DRD5 DRD4 DRD3 DRD2 BDNF
4
Show member pathways
12.58 SLC6A3 MAOA DRD5 DRD4 DRD3 DRD2
5 12.24 DRD5 DRD4 DRD3 DRD2
7 12.17 NPY HTR1B DRD5 DRD2 BDNF
8
Show member pathways
11.9 SLC6A3 MAOA DRD2 BDNF
9
Show member pathways
11.81 DRD4 DRD3 DRD2
10
Show member pathways
11.8 SLC6A4 CYP2D6 CYP2C19 COMT
11 11.72 SLC6A4 MAOA HTR1B CYP2D6 CYP2C19
12
Show member pathways
11.65 MAOA DBH COMT
13
Show member pathways
11.6 HTR1B DRD5 DRD4 DRD3 DRD2
14
Show member pathways
11.54 CYP2D6 CYP2C19 COMT
15 11.28 MAOA CYP2D6 CYP2C19
16
Show member pathways
11.26 SLC6A4 SLC6A3 MAOA DBH
17 11.13 SLC6A4 MAOA HTR1B
18 11 DRD5 DRD3 DRD2
19
Show member pathways